You just read:

Pulmatrix Receives Orphan Drug Designation from the FDA for Inhaled Drug to Treat Pulmonary Fungal Infections in Cystic Fibrosis Patients

News provided by

Pulmatrix, Inc.

17 Aug, 2016, 13:23 ET